Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: June 2011

Haberman Associates Multitargeted Therapies report published by CHI Insight Pharma Reports

Tweet  On June 1, 2011, Cambridge Healthtech Institute’s (CHI’s) Insight Pharma Reports announced the publication of our new book-length report, Multitargeted Therapies: Promiscuous Drugs and Combination Therapies. In the past 20 years or so, pharmaceutical and biotechnology industry R&D has been increasingly aimed at developing drugs to treat complex diseases such as cancer, cardiovascular disease,…

HDL-raising drugs revisited

Tweet    In our blog post of May 19, 2011, we discussed the late-stage development of two cholesterol ester transfer protein (CETP) inhibitors, designed to raise serum high-density lipoprotein (HDL), or “good cholesterol”. These agents are Merck’s anacetrapib and Roche’s dalcetrapib. The clinical results with these agents haveĀ  have reignited enthusiasm for CETP inhibitors in…